Safety Alert 001/12

Product Recall CSL Human Albumin

Background
The Therapeutic Goods Administration (TGA) has informed NSW Ministry of Health that current stocks of CSL Human Albumin (4% and 20%) may be contaminated with Ethylene Glycol. CSL and the TGA are arranging quarantining of Albumin.

Toxic levels of Ethylene Glycol can cause metabolic acidosis and renal failure.

It is unclear which batches of Albumin may be contaminated.

Further testing of batches will occur to see which batches will need to be returned to the supplier.

Mandatory actions for Local Health Districts/Networks
- Albumin is not to be used on patients unless clinically essential. See attached advice from TGA.
- All stocks of Albumin are to be quarantined and withdrawn from routine use until further notice.

References
- Advice from the TGA

Further information will be forwarded when available

Action required by Local Health Districts/Networks
1. Ensure all stocks of Albumex are quarantined and withdrawn from clinical use.
2. Report to CEC by 9 March 2012 when action complete